Abstract
Tepotinib is an oral, once daily (QD), highly selective, potent MET inhibitor, that has shown durable activity in METex14 skipping advanced NSCLC. Here, we report outcomes in Asian patients (pts) from VISION; these data are relevant to clinical practice as tepotinib is approved in several Asian countries; Japan, Taiwan, South Korea, Singapore, and is available in Hainan, China.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
